The overall goal of my clinical research and bench laboratory is to provide better care to patients with a rare disease of the lung blood vessels, pulmonary arterial hypertension (PAH). We provide care for patients from all over New York and central PA, and we use the full complement of approved PAH therapies. We also contribute actively to clinical research in hopes of better therapies with drugs that are already available. In my laboratory, we do experiments in animals and cells in an attempt to discover entirely new ways to treat this deadly disease.
Patient Care Bio
Dr. White's focus is to understand the vascular biology of pulmonary arterial hypertension (PAH) and to apply the best science in the care of patients. His lab uses a rat model of severe PAH (pneumonectomy and monocrotaline) and they measure the effects of PAH on exercise tolerance, hemodynamics, and angiography. They are testing novel small molecules that might be useful in treating patients with this devastating disease. Dr. White is currently treating ~130 patients for PAH with 30 patients on Remodulin or Flolan. We are actively enrolling in national clinical trials for PAH.
|Parker B. Francis Fellowship in Pulmonary Biology, Francis Family Foundation
||2005 - 2007
|Buswell Fellowship, Department of Medicine, University of Rochester SMD
||2003 - 2005
|NIH Training Grant Multi-Disciplinary Training & Pulmonary Research, University of Rochester SMD
||2001 - 2004
|Alpha Omega Alpha, University of Pittsburgh
|NIH Medical Scientist Training Program, University of Pittsburgh
||1990 - 1997
|Phi Beta Kappa, Ohio State University